Zenas BioPharma (ZBIO) Accounts Payables (2023 - 2026)

Zenas BioPharma's Accounts Payables history runs 4 years deep, the most recent figure standing at $8.9 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 55.32% year-over-year to $8.9 million; the TTM figure through Mar 2026 stood at $8.9 million (down 55.32% YoY), while the FY2025 annual figure was $7.1 million, down 58.5% from the prior year.
• Accounts Payables was $8.9 million for Q1 2026 at Zenas BioPharma, up from $7.1 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $20.0 million in Q1 2025 to a low of $5.4 million in Q4 2023.
• Historically, Accounts Payables has averaged $11.0 million across 4 years, with a median of $8.4 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables soared 217.57% in 2024, then sank 58.5% in 2025.
• A 4-year view of Accounts Payables shows it stood at $5.4 million in 2023, then jumped by 217.57% to $17.1 million in 2024, then sank by 58.5% to $7.1 million in 2025, then advanced by 25.78% to $8.9 million in 2026.
• The last three Accounts Payables figures came in at $8.9 million (Q1 2026), $7.1 million (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.